Sierra Oncology established a DDR Advisory Committee composed of experts in the cancer drug development field.
Sierra Oncology (NASDAQ:SRRA) established a DDR Advisory Committee composed of experts in the cancer drug development field.
As quoted in the press release:
The DDR Advisory Committee will advise Sierra’s management as it advances its DDR oriented development programs and seeks to maximize the potential clinical and commercial deployment of its drug candidates.
“A growing body of research has established that the DDR network is essential for cancer cell survival and adaptation. As such it presents fertile ground for generating innovative approaches to treat various cancers. To capitalize on this rapidly advancing and evolving science, we are collaborating closely with Cancer Research UK and the Institute of Cancer Research, institutions that are pioneers in DDR and the originators of our lead DDR asset, SRA737, which targets Chk1, a critical DDR regulator,” said Dr. Nick Glover, President and CEO of Sierra Oncology. “We believe the formation of our new DDR Advisory Committee, represented by leading experts in DDR biology, chemistry and medicine, will further strengthen our ability to remain at the forefront of this field and demonstrates our commitment to this promising new area in cancer treatment.”